URGN's Chief Medical Officer Sells Shares
Mark Schoenberg sold 10,000 shares of URGN, valued at $350,100, on June 22, 2026.
Key Points
- Mark Schoenberg, URGN's Chief Medical Officer, sold 10,000 shares on June 22, 2026, at an average price of $35.01, totaling $350,100.
- Shares of URGN traded near $35.80 on Wednesday, with major holders like BlackRock increasing their positions.
- Analysts from HC Wainwright & Co. and Oppenheimer maintained 'buy' ratings with price targets of $45 and $40, respectively.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Mark Schoenberg, the Chief Medical Officer of URGN, recently sold 10,000 shares of the company. The transaction took place on June 22, 2026, at an average price of $35.01 per share, amounting to a total of $350,100. This sale was planned and executed under a Rule 10b5-1 trading plan.
Other Institutional Activity in URGN
Institutional investors have been active in URGN. BlackRock, Inc. increased its holdings by 244,558 shares, bringing its total to 2,845,567 shares valued at approximately $51.16 million, marking a 9.4% increase. Toronto Dominion Bank opened a new position with 2,616,714 shares valued at $47.05 million. Kynam Capital Management, LP also initiated a new stake, acquiring 2,247,393 shares worth about $40.41 million. Meanwhile, Morgan Stanley slightly reduced its holdings by 2,863 shares, maintaining a total of 2,560,038 shares valued at $46.03 million.
UroGen Pharma Ltd. Stock Down 17.9%
Shares of URGN traded near $35.80 on Wednesday. The company has a market cap of $816.99 million. The stock has seen a 52-week low of $30.00 and a high of $40.00. Its 50-day moving average is $34.50, while the 200-day moving average stands at $33.00.
$URGN stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at UroGen Pharma Ltd.
Alongside Mark Schoenberg's sale, there was insider buying activity on the same day. Robinson James Jr. purchased 8,000 and 10,000 shares in separate transactions, while Leana Wen, Arie Belldegrun, Cynthia Butitta, and Daniel George Wildman each bought 10,000 shares. These transactions were not part of a pre-planned trading program.
Analysts Set New Price Targets
Analysts remain bullish on URGN. On May 11, 2026, HC Wainwright & Co. maintained its 'buy' rating with a price target of $45. Oppenheimer also kept a 'buy' rating on May 7, 2026, with a target of $40. Piper Sandler initiated coverage with a 'buy' rating and a target of $36 back in August 2025.
Bottom Line
Mark Schoenberg's planned sale of URGN shares is part of a broader landscape of active trading around the stock. Institutional investors like BlackRock are increasing their positions, suggesting continued interest in URGN. Analysts maintain a positive outlook, with multiple firms reiterating 'buy' ratings and setting robust price targets. As always, it's essential to remember that insider transactions and analyst ratings are just pieces of the puzzle when evaluating a stock.
Get UroGen Pharma Ltd. alerts
New 13F filings, insider trades, and analyst moves on $URGN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.